Analysts Offer Insights on Healthcare Companies: Audentes Therapeutics (NASDAQ: BOLD) and Rexahn Pharma (NASDAQ: REXN)

By Ryan Adsit

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Audentes Therapeutics (BOLDResearch Report) and Rexahn Pharma (REXNResearch Report).

Audentes Therapeutics (BOLD)

Mizuho Securities analyst Difei Yang reiterated a Buy rating on Audentes Therapeutics today and set a price target of $45. The company’s shares closed yesterday at $37.03.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 5.5% and a 39.1% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Alder Biopharmaceuticals, and Revance Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Audentes Therapeutics with a $46.50 average price target, a 25.6% upside from current levels. In a report issued on July 29, Raymond James also resumed coverage with a Buy rating on the stock with a $46 price target.

See today’s analyst top recommended stocks >>

Rexahn Pharma (REXN)

In a report released today, Joseph Pantginis from H.C. Wainwright downgraded Rexahn Pharma to Hold, with a price target of $3. The company’s shares closed yesterday at $4.93, close to its 52-week low of $4.71.

According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -12.8% and a 27.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rexahn Pharma with a $23 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.